Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PSNL

Personalis Inc

Sep 20 • 04:00PM ET

5.74

Dollar change -0.19
Percentage change -3.20	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKG VTI VXF IWC AVSC DFAS DFUS DCOR DFAU RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.63	Insider Own	40.48%	Shs Outstand	50.48M	Perf Week	0.88%
Market Cap	305.37M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	19.25%	Shs Float	31.66M	Perf Month	-9.46%
Income	-81.45M	PEG	-	EPS next Q	-0.35	Inst Own	48.63%	Short Float	7.17%	Perf Quarter	370.49%
Sales	80.03M	P/S	3.82	EPS this Y	45.48%	Inst Trans	-2.99%	Short Ratio	1.56	Perf Half Y	293.15%
Book/sh	2.12	P/B	2.71	EPS next Y	-1.36%	ROA	-37.49%	Short Interest	2.27M	Perf Year	334.85%
Cash/sh	1.63	P/C	3.51	EPS next 5Y	-13.70%	ROE	-56.49%	52W Range	0.89 - 7.20	Perf YTD	173.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.46%	ROI	-54.48%	52W High	-20.28%	Beta	1.92
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	18.20%	Gross Margin	27.76%	52W Low	544.51%	ATR (14)	0.60
Dividend Ex-Date	-	Current Ratio	3.18	EPS Y/Y TTM	30.89%	Oper. Margin	-101.13%	RSI (14)	57.30	Volatility	10.07% 10.59%
Employees	225	Debt/Eq	0.42	Sales Y/Y TTM	19.20%	Profit Margin	-101.78%	Recom	1.33	Target Price	7.05
Option/Short	Yes / Yes	LT Debt/Eq	0.33	EPS Q/Q	51.38%	Payout	-	Rel Volume	0.84	Prev Close	5.93
Sales Surprise	17.20%	EPS Surprise	35.71%	Sales Q/Q	35.22%	Earnings	Aug 07 AMC	Avg Volume	1.45M	Price	5.74
SMA20	2.27%	SMA50	31.76%	SMA200	161.84%	Trades		Volume	1,219,565	Change	-3.20%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22
Jul-15-19	Initiated	Oppenheimer	Outperform	$29
Jul-15-19	Initiated	Morgan Stanley	Overweight	$28
Jul-15-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-16-24 09:00AM	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal MRD Test (Business Wire)
Aug-22-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -9.94%
Aug-21-24 06:13PM	Why Tempus AI Stock Skyrocketed Nearly 22% Today (Motley Fool) +11.42%
Aug-19-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-16-24 08:30AM	Personalis and Tempus Announce Expanded Collaboration (Business Wire) +18.15%
09:15AM	Loading…
Aug-13-24 09:15AM	Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.12%
Aug-07-24 05:30PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.00% +19.10%
04:35PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Jul-31-24 04:01PM	Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference (Business Wire) +10.58%
Jul-24-24 04:01PM	Personalis to Announce Second Quarter 2024 Financial Results (Business Wire)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire) +9.68%
Jun-18-24 04:01PM	Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference (Business Wire)
Jun-13-24 08:00AM	Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call (Business Wire)
04:05PM	Loading…
Jun-04-24 04:05PM	ASCO Data Highlights NeXT Personal Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring (Business Wire) -6.90% +8.89%
May-31-24 09:05AM	Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus (Business Wire)
May-22-24 09:05AM	Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 (Business Wire) +7.24%
May-17-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-24 12:31PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.43%
07:11AM	Q1 2024 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
04:00AM	Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ... (GuruFocus.com)
May-08-24 08:59PM	PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:22PM	Personalis: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 04:01PM	Personalis to Announce First Quarter 2024 Financial Results (Business Wire) -5.80%
Mar-28-24 04:01PM	Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
09:00AM	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-26-24 09:00AM	Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Business Wire)
Mar-19-24 04:43PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.79%
09:44AM	Loading…
Feb-29-24 09:44AM	Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.16%
Feb-28-24 05:00PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-14-24 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +10.46%
Jan-31-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-24 09:00AM	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Business Wire) -8.50%
Jan-17-24 04:15PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.06% -7.43%
Jan-16-24 09:05AM	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Business Wire) -5.17%
Jan-05-24 09:05AM	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Business Wire) +7.00%
Dec-04-23 09:15AM	Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives (Business Wire) +6.80%
Nov-28-23 04:15PM	Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing (Business Wire) -8.33% -9.09%
Nov-16-23 04:05PM	Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers (GlobeNewswire) -7.21% +6.80%
03:03PM	Meet the biotech company Cathie Wood bought half a million shares of this month (TheStreet.com)
Nov-08-23 01:45PM	Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript (Insider Monkey) +21.52%
Nov-07-23 04:50PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance) -9.17%
04:01PM	Personalis Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 08:15AM	Personalis Launches NeXT Personal Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer (Business Wire)
Oct-24-23 04:01PM	Personalis to Announce Third Quarter 2023 Financial Results (Business Wire) +15.04% -8.41%
Oct-21-23 04:25AM	Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology (Business Wire)
Oct-19-23 07:15AM	Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023 (Business Wire)
Oct-18-23 07:15AM	Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance (Business Wire)
Aug-29-23 04:01PM	Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference (Business Wire) +7.95%
Aug-24-23 07:01PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.41%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-08-23 05:40PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jul-25-23 04:01PM	Personalis to Announce Second Quarter 2023 Financial Results (Business Wire)
Jul-13-23 06:51AM	Personalis (NASDAQ:PSNL) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 86% (Simply Wall St.)
Jun-26-23 05:00PM	Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics (Business Wire)
Jun-13-23 07:01PM	Dr. Kenneth J. Widder Joins Personalis Board of Directors (Business Wire) -6.93%
Jun-08-23 10:49AM	Not Many Are Piling Into Personalis, Inc. (NASDAQ:PSNL) Just Yet (Simply Wall St.)
May-30-23 08:00AM	Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023 (Business Wire) -6.22%
May-16-23 08:00AM	Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer (Business Wire) -6.36%
May-07-23 03:07PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 12:03PM	Companies Like Personalis (NASDAQ:PSNL) Could Be Quite Risky (Simply Wall St.)
May-04-23 01:03PM	Q1 2023 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:45PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.00%
04:37PM	Personalis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Personalis Reports First Quarter 2023 Financial Results (Business Wire)
May-02-23 08:00AM	Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer (Business Wire) -5.17%
Apr-19-23 04:01PM	Personalis to Announce First Quarter 2023 Financial Results (Business Wire) -7.17%
Apr-08-23 08:10AM	Personalis, Inc. (NASDAQ:PSNL) is favoured by institutional owners who hold 62% of the company (Simply Wall St.)
Apr-05-23 04:01PM	Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
08:45AM	Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study (Business Wire)
Mar-22-23 08:55AM	Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023 (Business Wire)
Mar-07-23 08:55AM	Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay (Business Wire)
Mar-02-23 04:05PM	Personalis Appoints Christopher Hall as Chief Executive Officer (Business Wire) +7.25%
Feb-28-23 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-26-23 07:31AM	Personalis Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Feb-24-23 01:32PM	Q4 2022 Personalis Inc Earnings Call (Thomson Reuters StreetEvents) -7.23%
Feb-23-23 04:01PM	Personalis Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-09-23 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-07-23 10:07AM	15 Worst Stock Picks of Cathie Wood in 2022 (Insider Monkey) +7.47%
Feb-06-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
01:41PM	Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down (Benzinga)
Feb-03-23 12:38PM	Why Personalis Shares Are Trading Higher Today (Benzinga) +28.29%
08:45AM	Personalis and Moderna Sign New Agreement to Leverage NeXT Platform in Personalized mRNA Cancer Vaccine Clinical Trials (Business Wire)
Jan-19-23 10:17AM	Fremont cancer test business Personalis to cut staff by one-third (American City Business Journals) -9.43%
04:31AM	Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce (Benzinga)
Jan-05-23 05:21AM	Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
Jan-04-23 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue (Business Wire) +8.46%
Dec-16-22 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.52% -8.84%
Dec-14-22 04:02PM	Personalis Announces CEO Retirement and Transition (Business Wire) -14.81%
Nov-30-22 08:55AM	Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer (Business Wire) +9.96%
Nov-21-22 04:01PM	Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-22 04:05PM	Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire) -8.30%
02:16PM	Here's Why Personalis (NASDAQ:PSNL) Must Use Its Cash Wisely (Simply Wall St.)
Nov-02-22 05:15PM	Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tempus AI, Inc.	10% Owner	Aug 16 '24	Buy	5.07	3,500,000	17,745,000	12,718,800	Aug 20 04:17 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 30 '24	Sale	2.97	524	1,556	127,227	Aug 01 05:16 PM
Tachibana Aaron	CFO AND COO	Jul 30 '24	Sale	2.97	742	2,204	175,270	Aug 01 05:13 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jun 17 '24	Sale	1.29	5,055	6,521	127,751	Jun 20 04:55 PM
Tachibana Aaron	CFO AND COO	Jun 17 '24	Sale	1.29	7,176	9,257	176,012	Jun 20 04:54 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Jun 17 '24	Sale	1.29	1,585	2,045	69,081	Jun 20 04:53 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	May 17 '24	Sale	1.38	940	1,297	132,806	May 21 09:14 PM
Tachibana Aaron	CFO AND COO	May 17 '24	Sale	1.38	1,333	1,840	183,188	May 21 09:13 PM
Moore Stephen Michael	SVP and Chief Legal Officer	May 17 '24	Sale	1.38	1,731	2,389	70,666	May 21 09:11 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Apr 30 '24	Sale	1.37	4,523	6,197	72,397	May 02 05:52 PM
MYERS WOODROW A JR	Director	Mar 01 '24	Buy	1.67	10,000	16,700	26,116	Mar 05 05:15 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jan 29 '24	Sale	1.37	526	721	128,870	Jan 31 04:30 PM
Tachibana Aaron	CFO AND COO	Jan 29 '24	Sale	1.37	716	981	184,521	Jan 31 04:27 PM
Chen Richard	Chief Medical Officer and EVP	Dec 15 '23	Sale	1.47	4,708	6,921	129,396	Dec 19 06:09 PM
Tachibana Aaron	CFO and COO	Dec 15 '23	Sale	1.47	6,747	9,918	185,237	Dec 19 06:07 PM
Moore Stephen Michael	General Counsel	Dec 15 '23	Sale	1.47	1,476	2,170	76,920	Dec 19 06:02 PM
Moore Stephen Michael	General Counsel	Nov 16 '23	Sale	1.04	1,722	1,791	78,396	Nov 20 04:30 PM
Tachibana Aaron	CFO and COO	Nov 16 '23	Sale	1.04	1,344	1,398	191,984	Nov 20 04:30 PM
Chen Richard	Chief Medical Officer and EVP	Nov 16 '23	Sale	1.04	940	978	124,104	Nov 20 04:30 PM
Hall Christopher M	President and CEO	Nov 01 '23	Sale	0.93	20,459	19,027	204,541	Nov 03 09:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSNL

Personalis Inc

Upgrade your FINVIZ experience